Using single-cell approaches in clinically annotated samples, we found that, prior to CART19 therapy, CD19pos pro-B-like tumor cells with low levels of IKAROS were associated with CD19 loss and CD19neg relapse. The gene discussed is CD19; the disease is neoplasm.